Back
2018
Deal

China Medical System Holdings invests in VAXIMM

VAXIMM AG, a company focused on developing oral T-cell immunotherapies, entered into development and commercialization collaboration agreement with and received an equity investment by China Medical System Holdings Limited (CMS) (HKSE:0867). VAXIMM is a privately held biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China.

VISCHER AG advises Vaximm AG regarding the equity Investment. The team is led by Matthias Staehelin (Partner) with Angelo Imperiale (Associate) both Corporate.

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions